IL266174B2 - Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications - Google Patents

Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Info

Publication number
IL266174B2
IL266174B2 IL266174A IL26617419A IL266174B2 IL 266174 B2 IL266174 B2 IL 266174B2 IL 266174 A IL266174 A IL 266174A IL 26617419 A IL26617419 A IL 26617419A IL 266174 B2 IL266174 B2 IL 266174B2
Authority
IL
Israel
Prior art keywords
dose
infusion
ifny
initial
seq
Prior art date
Application number
IL266174A
Other languages
English (en)
Hebrew (he)
Other versions
IL266174A (en
IL266174B1 (en
Original Assignee
Novimmune Sa
Emaco Sa
Swedish Orphan Biovitrum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Emaco Sa, Swedish Orphan Biovitrum Ag filed Critical Novimmune Sa
Publication of IL266174A publication Critical patent/IL266174A/en
Publication of IL266174B1 publication Critical patent/IL266174B1/en
Publication of IL266174B2 publication Critical patent/IL266174B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL266174A 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications IL266174B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411783P 2016-10-24 2016-10-24
PCT/IB2017/001427 WO2018078442A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Publications (3)

Publication Number Publication Date
IL266174A IL266174A (en) 2019-06-30
IL266174B1 IL266174B1 (en) 2024-06-01
IL266174B2 true IL266174B2 (en) 2024-10-01

Family

ID=60957345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266174A IL266174B2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Country Status (12)

Country Link
EP (1) EP3528845A2 (OSRAM)
JP (3) JP2019532970A (OSRAM)
KR (2) KR20190071785A (OSRAM)
CN (1) CN110167593A (OSRAM)
AU (2) AU2017352033A1 (OSRAM)
BR (1) BR112019008156A2 (OSRAM)
CA (2) CA3244670A1 (OSRAM)
EA (1) EA201990930A1 (OSRAM)
IL (1) IL266174B2 (OSRAM)
MX (2) MX2019004766A (OSRAM)
SG (1) SG11201903659WA (OSRAM)
WO (1) WO2018078442A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CA2985001A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
CN108884459B (zh) * 2016-04-26 2024-04-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
WO2021207150A1 (en) * 2020-04-06 2021-10-14 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
US7183390B2 (en) * 1998-12-01 2007-02-27 Pdl Biopharma, Inc. Humanized antibodies to gamma-interferon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
HK1203519A1 (en) * 2011-11-23 2015-10-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma
US20170189528A1 (en) 2014-06-10 2017-07-06 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab formulation
CA2985001A1 (en) * 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183390B2 (en) * 1998-12-01 2007-02-27 Pdl Biopharma, Inc. Humanized antibodies to gamma-interferon
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
US20140186362A1 (en) * 2005-01-27 2014-07-03 Novlmmune S.A. Anti-Interferon Gamma Antibodies And Methods Of Use Thereof

Also Published As

Publication number Publication date
MX2019004766A (es) 2019-09-27
JP2019532970A (ja) 2019-11-14
KR20190071785A (ko) 2019-06-24
IL266174A (en) 2019-06-30
CA3244670A1 (en) 2025-11-29
JP7562074B2 (ja) 2024-10-07
IL266174B1 (en) 2024-06-01
CA3041434A1 (en) 2018-05-03
EP3528845A2 (en) 2019-08-28
AU2024264563A1 (en) 2024-11-28
WO2018078442A2 (en) 2018-05-03
EA201990930A1 (ru) 2019-11-29
KR20240148970A (ko) 2024-10-11
AU2017352033A1 (en) 2019-06-06
JP2024170569A (ja) 2024-12-10
CN110167593A (zh) 2019-08-23
BR112019008156A2 (pt) 2019-07-02
JP2022187025A (ja) 2022-12-15
WO2018078442A3 (en) 2018-08-23
MX2025012950A (es) 2025-12-01
SG11201903659WA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US12275785B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
US12195530B2 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP7562074B2 (ja) インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
Pardeo et al. Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies
Henrie et al. Inflammatory diseases in hematology: a review
da Silva Filha et al. Idiopathic nephrotic syndrome in pediatrics: an up-to-date
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
EA049189B1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
Pile et al. Disease-modifying anti-rheumatic drugs
JAK et al. Author Queries